How has BioLineRx (BLRX) stock been impacted by COVID-19?
BLRX trades on heavy volume after compelling Phase 3 Trials of Motixafortide (BL-8040) for the cancer treatment. BioLineRx Ltd. (BLRX), a clinical-stage biopharmaceutical firm announced today that it has obtained positive results from an interim analysis of its GENESIS Phase 3 trial of motixafortide (BL-8040) for stem cell mobilization (SCM) in multiple myeloma patients. Multiple myeloma is […]
